In the phase III KESTREL trial (NCT02551159), neither tumor PD-L1 expression (TC ≥ 50%/IC ≥ 25% or TC ≥ 25%) nor a low neutrophil-to-lymphocyte ratio (≤7) enriched for improved outcomes with first-line durvalumab (D) or durvalumab + tremelimumab (D + T) versus EXTREME. This evidence concerns the gene CD274 and neoplasm.